// App-Quantinova.ai

POS1042 (2021) : EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

Researchers

Presenter

  • A. Armstrong

Principal Investigators

  • M. Gooderham

  • R. B. Warren

  • K. Papp

  • B. Strober

  • D. Thai

  • E. Colston

  • J. Throup

  • S. Kundu

  • S. Banerjee

  • A. Blauvelt

Medical Centers

  • Keck School of Medicine, University of Southern California, Clinical Research, Los Angeles, United States of America

  • SKiN Center for Dermatology, Queen’s University and Probity Medical Research, Peterborough, Canada

  • The Dermatology Centre, Salford Royal NHS Foundations Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, University of Manchester, Manchester, UK

  • Clinical Research and Probity Medical Research, K. Papp Clinical Research, Waterloo, Canada

  • Yale University, New Haven, United States of America

  • Central Connecticut Dermatology Research, Cromwell, CT, United States of America

  • University of Lübeck, Comprehensive Centre for Inflammation Medicine, Lübeck, Germany

  • Bristol-Myers Squibb, former employee, Princeton, United States of America

  • Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America

  • Oregon Medical Research Center, Dermatology, Portland, United States of America

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

Phase

  • III

Study Id's

  • NCT03624127

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved